Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

@article{Hutchings2005PrognosticVO,
  title={Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.},
  author={Martin Hutchings and Nabegh George Mikhaeel and Paul A. Fields and Tom O Nunan and A. R. Timothy},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2005},
  volume={16 7},
  pages={1160-8}
}
BACKGROUND Long-term survival from Hodgkin lymphoma (HL) is 80-90%, but the treatment has serious late adverse effects. Modern risk-adapted treatment requires accurate assessment of the patient's prognosis. This investigation assessed the value of positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two or three cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS A total of 85 patients with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 121 extracted citations

Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma.

Hematology. American Society of Hematology. Education Program • 2006
View 7 Excerpts
Highly Influenced

Interim FDG-PET Imaging in Lymphoma.

Seminars in nuclear medicine • 2018
View 9 Excerpts
Highly Influenced

Current role of FDG PET/CT in lymphoma

European Journal of Nuclear Medicine and Molecular Imaging • 2013
View 2 Excerpts
Highly Influenced

Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2013
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…